GOOD or BAD responder? Behavioural and neuroanatomical markers of clinical response to donepezil in dementia

Behavioural Neurology

Volumn 25, Issue 2, 2012, Pages 61-72

  Bottini, Gabriella ^a,b   Berlingeri, Manuela ^c   Basilico, Stefania ^b   Passoni, Serena ^b   Danelli, Laura ^c   Colombo, Nadia ^b   Sberna, Maurizio ^b   Franceschi, Massimo ^d   Sterzi, Roberto ^b   Paulesu, Eraldo ^c,e  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Neurology Department   (Italy)

^e IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Acetilcholinesterase inhibitors; Alzheimer's disease; donepezil; MRI; voxel based morphometry

Indexed keywords

ACETYLCHOLINE; DONEPEZIL;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BRAIN ATROPHY; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GRAY MATTER; HUMAN; MINI MENTAL STATE EXAMINATION; MORPHOMETRICS; NEUROANATOMY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SUBSTANTIA INNOMINATA; TREATMENT OUTCOME; VOXEL BASED MORPHOMETRY; WHITE MATTER;

EID: 84858654338     PISSN: 09534180     EISSN: 18758584     Source Type: Journal    
DOI: 10.3233/BEN-2011-0359     Document Type: Article

References (63)

1. A.E. Guttmacher and F.S. Collins, Welcome to the genomic era, N Engl J Med 349(10) (2003), 996-998. (Pubitemid 37064775)
2. N. Vanacore, C. Sorrentino, B. Caffari, F. Ravaioli, M. Maggini and R. Raschetti, Epidemiologia della demenza di Alzheimer in Italia e valutazioni sul numero di pazienti inclusi nel progetto Cronos, Newsletter Progetto Cronos 1 (2002), 3-6.
3. P.T. Francis, A.M. Palmer, M. Snape and G.K. Wilcock, The cholinergic hypothesis of Alzheimer's disease: a review of progress, J Neurol Neurosurg Psychiatry 66(2) (1999), 137-147. (Pubitemid 29103513)
4. M. Pákáski and J. Kálmán, Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease, Neurochem Int 53(5) (2008), 103-111.
5. E.D. Levin, F.J. McClernon and A.H. Rezvani, Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization, Psychopharmacology (Berl) 184(3-4) (2006), 523-539. (Pubitemid 43255869)
6. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci and M. Kivipelto, Alzheimer's disease: clinical trials and drug development, Lancet Neurol 9(7) (2010), 702-716.
7. E. Rota, P. Ferrero, R. Ursone and G. Migliaretti, Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer's disease: A starting point to explore Bayesian approximation in clinical practice, Bioinformation 2(2) (2007), 43-49.
8. J. Birks, Cholinesterase inhibitors for Alzheimer's disease, Cochrane Database Syst Rev (1) (2006), p. CD005593.
9. R. Cacabelos, Pharmacogenomics in Alzheimer's disease, Methods Mol Biol 448 (2008), 213-357.
10. P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker and M. Oremus, Effectiveness of cholinesterase inhibitors andmemantine for treating dementia: evidence review for a clinical practice guideline, Ann Intern Med 148(5) (2008), 379-397. (Pubitemid 351665469)
11. R.C. Mohs, R.S. Doody, J.C. Morris, J.R. Ieni, S.L. Rogers, C.A. Perdomo and R.D. Pratt, A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients, Neurology 57 (2001), 481-488. (Pubitemid 32757597)
12. B. Winblad, K. Engedal and H. Soininen, A 1-year, randomized, placebo-controlled study of Donepezil in patients with mild to moderate AD, Neurology 57 (2001), 489-495. (Pubitemid 32757598)
13. R. Raschetti, F. Menniti Ippolito, E. Forcella and C. Bianchi, Complementary and alternative medicine in the scientific literature, Journal of Alternative and Complementary Medicine 11(1) (2005), 209-212. (Pubitemid 40328137)
14. J.S. Birks, D. Melzer and H. Beppu, Donepezil for mild and moderate Alzheimer's disease, Cochrane Database Syst Rev (4) (2000), CD001190.
15. C. Loy and L. Schneider, Galantamine for Alzheimer's disease, Cochrane Database Syst Rev (4) (2004), CD001747.
16. J. Birks and R.J. Harvey, Donepezil for dementia due to Alzheimer's disease, Cochrane Database Syst Rev (1) (2006), CD001190.
17. C. Courtney, D. Farrell, R. Gray, R. Hills, L. Lynch, E. Sellwood, S. Edwards, W. Hardyman, J. Raftery, P. Crome, C. Lendon, H. Shaw and P. Bentham, Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial, Lancet 363(9427) (2004), 2105-2115.
18. M. Pugliatti, P. Sobocki, E. Beghi, S. Pini, G.B. Cassano, A.C. Altamura, S. Pozzoli and G. Rosati, Cost of disorders of the brain in Italy, Neurol Sci 29(2) (2008), 99-107. (Pubitemid 351696411)
19. K. Blennow, H. Hampel, M. Weiner and H. Zetterberg, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, Nat Rev Neurol 6(3), 131-144.
20. F. Nobili, M. Koulibaly, P. Vitali, O. Migneco, G. Mariani, K. Ebmeier, A. Pupi, P. Robert, G. Rodriguez and J. Darcourt, Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors, J Nucl Med 43(8) (2002), 983-990. (Pubitemid 34847919)
21. S. Shimizu, H. Hanyu, T. Iwamoto, K. Koizumi and K. Abe, SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease, J Neuroimaging 16(1) (2006), 16-23. (Pubitemid 43238060)
22. J. Ashburner and K.J. Friston, Voxel-based morphometry - the methods, Neuroimage 11(6 Pt 1) (2000), 805-821. (Pubitemid 30437668)
23. C.D. Good, I.S. Johnsrude, J. Ashburner, R.N.A. Henson, K.J. Friston and S.J. Frackowiak, A voxel-based morphometric study of ageing in 465 normal adult human brains, Neuroimage 14 (2001), 21-36. (Pubitemid 32552740)
24. A. Venneri, W.J. McGeown and M.F. Shanks, Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease, Neuroreport 16(2) (2005), 107-110. (Pubitemid 40250379)
25. A. Venneri and R. Lane, Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease, Neuroreport 20(3) (2009), 285-288.
26. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price and E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34(7) (1984), 939-944. (Pubitemid 14076461)
27. M.F. Folstein, S.E. Folstein and P.R. McHugh, "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res 12(3) (1975), 189-198.
28. J. Raven, CPM. Coloured Progressive Matrices. 1984, OS, Firenze.
29. H. Spinnler and G. Tognoni, Standardizzazione e taratura italiana di test neuropsicologici. Vol. Supplementum N.8. 1987, Milano: Masson Italia Periodici.
30. A.R.Giovagnoli,M.Del Pesce, S.Mascheroni,M. Simoncelli, M. Laiacona and E. Capitani, Trail making test: normative values from 287 normal adult controls, Ital J Neurol Sci 17(4) (1996), 305-309. (Pubitemid 126764956)
31. A. Orsini, D. Grossi, E. Capitani, M. Laiacona, C. Papagno and G. Vallar, Verbal and spatial immediate memory span: normative data from 1355 adults and 1112 children, Ital J Neurol Sci 8(6) (1987), 539-548.
32. G.Novelli, C. Papagno and E.Capitani, Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali, Archivio di psicologia neurologia e psichiatria 47 (1986), 477-506.
33. S. Katz, T.D. Downs, H.R. Cash and R.C. Grotz, Progress in development of the index of ADL, Gerontologist 10(1) (1970), 20-30.
34. M. Lawton and E. Brody, Assessment of older people: selfmaintaining and instrumental activities of daily living, Gerontologist 9(3) (1969), 179-186.
35. M. Trabucchi, Le demenze. 4 ed. 2005: Utet Div. Scienze Mediche.
36. N.S. Jacobson and P. Truax, Clinical significance: a statistical approach to defining meaningful change in psychotherapy research, J Consult Clin Psychol 59(1) (1991), 12-19.
37. C.R. Genovese, N.A. Lazar and T. Nichols, Thresholding of statistical maps in functional neuroimaging using the false discovery rate, Neuroimage 15(4) (2002), 870-878. (Pubitemid 34852500)
38. S.J. Teipel, W.H. Flatz, H. Heinsen, A.L. Bokde, S.O. Schoenberg, S. Stockel, O. Dietrich, M.F. Reiser, H.J. Moller and H. Hampel, Measurement of basal forebrain atrophy in Alzheimer's disease using MRI, Brain 128(Pt 11) (2005), 2626-2644. (Pubitemid 41552947)
39. C. Rorden, H.O. Karnath and L. Bonilha, Improving lesionsymptom mapping, J Cogn Neurosci 19(7) (2007), 1081-1088.
40. C. Rorden and M. Brett, Stereotaxic display of brain lesions, Behav Neurol 12(4) (2000), 191-200. (Pubitemid 32843166)
41. S. Mori, S. Wakana, L.M. Nagae-Poetscher and P.C. van Zijl, MRI Atlas of Human White Matter. 2005, Amsterdam, The Netherlands: Elsevier.
42. G.Measso, F. Cavarzeran, G. Zappalà, B. Lebowitz, T. Crook, F. Pirozzolo, L. Amaducci, D. Masari and F. Grigoletto, The Mini-Mental State examination: normative study of an italian random sample, Dev Neuropsychol 9 (1993), 77-85.
43. F. Cortes, F. Nourhashemi, O. Guerin, C. Cantet, S. Gillette- Guyonnet, S. Andrieu, P.J. Ousset and B. Vellas, Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study, Alzheimers Dement 4(1) (2008), 22-29.
44. G. Chetelat and J.C. Baron, Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging, Neuroimage 18 (2003), 525-541. (Pubitemid 36269160)
45. G.B. Karas, P. Scheltens, S.A.R.B. Rombouts, P.J.Visser, R.A. van Schijndel, N.C. Fox and F. Barkhof, Global and local graymatter loss inmild cognitive impairment andAlzheimer's disease, Neuroimage 23 (2004), 708-716. (Pubitemid 39370621)
46. E. Paulesu, B. Goldacre, P. Scifo, S.F. Cappa, M.C. Gilardi, I. Castiglioni, D. Perani and F. Fazio, Functional heterogeneity of left inferior frontal cortex as revealed by fMRI, Neuroreport 8(8) (1997), 2011-2017.
47. D.T. Stuss and M.P. Alexander, Executive functions and the frontal lobes: a conceptual view, Psychol Res 63(3-4) (2000), 289-298.
48. A.D. Baddeley, H.A. Baddeley, R.S. Bucks and G.K.Wilcock, Attentional control in Alzheimer's disease, Brain 124(Pt 8) (2001), 1492-1508. (Pubitemid 32726764)
49. S.E. MacPherson, S. Della Sala, R.H. Logie and G.K.Wilcock, Specific AD impairment in concurrent performance of two memory tasks, Cortex 43(7) (2007), 858-865. (Pubitemid 47517038)
50. S. Belleville, H. Chertkow and S. Gauthier, Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment, Neuropsychology 21(4) (2007), 458-469. (Pubitemid 47445217)
51. J.D. Huntley and R.J. Howard, Working memory in early Alzheimer's disease: a neuropsychological review, Int J Geriatr Psychiatry 25(2), 121-132.
52. D.P. Salmon and M.W. Bondi, Neuropsychological assessment of dementia, Annu Rev Psychol 60 (2009), 257-282.
53. R.I. Scahill, J.M. Schott, J.M. Stevens, M.N. Rossor and N.C. Fox, Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI, Proc Natl Acad Sci U S A 99(7) (2002), 4703-4707. (Pubitemid 34286048)
54. N.R. Selden, D.R. Gitelman, N. Salamon-Murayama, T.B. Parrish and M.M. Mesulam, Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain, Brain 121 (Pt 12) (1998), 2249-2257. (Pubitemid 28552464)
55. J.W. Dalley, J. McGaughy, M.T. O'Connell, R.N. Cardinal, L. Levita and T.W. Robbins, Distinct changes in cortical acetylcholine and noradrenaline efflux during contingent and noncontingent performance of a visual attentional task, J Neurosci 21(13) (2001), 4908-4914. (Pubitemid 32565649)
56. T.W. Robbins and A.C. Roberts, Differential regulation of fronto-executive function by the monoamines and acetylcholine, Cereb Cortex 17(Suppl 1) (2007), i151-160.
57. H. Hampel, K. Burger, S.J. Teipel, A.L. Bokde, H. Zetterberg and K. Blennow, Core candidate neurochemical and imaging biomarkers of Alzheimer's disease, Alzheimers Dement 4(1) (2008), 38-48.
58. S.J. Teipel, M. Ewers, S. Wolf, F. Jessen, H. Kolsch, S. Arlt, C. Luckhaus, P. Schonknecht, K. Schmidtke, I. Heuser, L. Frolich, G. Ende, J. Pantel, J. Wiltfang, F. Rakebrandt, O. Peters, C. Born, J. Kornhuber and H. Hampel, Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease, Psychiatry Res 182(3), 244-250.
59. R.C. Petersen, G.E. Smith, S.C.Waring, R.J. Ivnik, E.G. Tangalos and E. Kokmen, Mild cognitive impairment: clinical characterization and outcome, Arch Neurol 56(3) (1999), 303- 308.
60. M. Grothe, L. Zaborszky, M. Atienza, E. Gil-Neciga, R. Rodriguez-Romero, S.J. Teipel, K. Amunts, A. Suarez- Gonzalez and J.L. Cantero, Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease, Cereb Cortex 20(7) (2010), 1685-1695.
61. H. Hampel, G.Wilcock, S. Andrieu, P. Aisen, K. Blennow, K. Broich,M. Carrillo, N.C. Fox, G.B. Frisoni,M. Isaac, S. Lovestone, A. Nordberg, D. Prvulovic, C. Sampaio, P. Scheltens, M. Weiner, B. Winblad, N. Coley and B. Vellas, Biomarkers for Alzheimer's disease therapeutic trials, Prog Neurobiol.
62. S.H. Choi, S.Y. Kim, H.R. Na, B.K. Kim, D.W. Yang, J.C. Kwon and M.Y. Park, Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease, Dement Geriatr Cogn Disord 25(5) (2008), 445-450. (Pubitemid 351630078)
63. G.C. Chiang, P.S. Insel, D. Tosun, N. Schuff, D. Truran- Sacrey, S.T. Raptentsetsang, C.R. Jack, Jr., P.S. Aisen, R.C. Petersen and M.W. Weiner, Hippocampal atrophy rates and CSF biomarkers in elderlyAPOE2 normal subjects, Neurology 75(22), 1976-1981.